TESSEN SOLUTIONS LIMITED

Their core work

Tessen Solutions (trading as Gasgon Medical) is an Irish medical device SME that develops safety hardware for intravenous infusion — specifically devices that remove air bubbles from IV lines to prevent potentially fatal air embolism, and break-away connectors that safely disconnect if a line is pulled, stopping accidental dislodgement. Their second and larger programme, SAFE-Infusion, extended this into closed system transfer devices that protect nurses and pharmacists from exposure to hazardous drugs such as chemotherapy agents during preparation and administration. The company targets both hospital settings and home care oncology, where the risks of IV therapy mishaps are highest and existing solutions are inadequate.

What they specialise in

How they've shifted over time

With only two projects and no recorded keywords for the first (Gasgon, 2020), a long-arc trend analysis is not possible. What is visible is a rapid scope expansion: the 2020 feasibility validated a single-function air-removal device concept, while the 2021 Innovation Action broadened the mission to a multi-failure-mode IV safety platform covering air embolism, hazardous drug containment, mechanical dislodgement, and remote monitoring. In just one project cycle, the company moved from a single-device startup pitch to a funded multi-partner clinical safety programme — a fast maturation typical of a well-executed SME Instrument phase-1-to-phase-2 trajectory.

The company is expanding from a single clinical hardware device toward an integrated IV safety system that includes hazardous drug containment and remote monitoring — suggesting future interest in digital health integration and regulatory clearance across multiple device classes.

How they like to work

Tessen/Gasgon Medical led their own SME-1 feasibility project as coordinator before joining the larger SAFE-Infusion Innovation Action as a participant, which is the classic SME Instrument progression — validate the concept independently, then embed the technology in a multi-partner scale-up programme. Their total consortium footprint is small: 5 unique partners across 4 countries, suggesting focused, purposeful partnerships rather than broad networking. They appear to choose partners that serve specific functions (clinical validation, regulatory, distribution) rather than building large research networks.

Gasgon Medical has worked with 5 unique consortium partners across 4 countries — a tight, function-driven network consistent with an early-stage medical device company selecting partners for clinical access, regulatory expertise, and market entry rather than research breadth. Their geographic base is Ireland with a European project reach.

What sets them apart

Gasgon Medical occupies a narrow but clinically significant niche: the mechanical safety of the IV line itself — an area where device innovation has lagged behind drug and digital innovation. Their combination of air embolism prevention, hazardous drug containment, and dislodgement protection in a single product family addresses three distinct IV adverse event categories that are normally handled separately or not at all. For consortium builders in clinical safety, home care technology, or oncology drug delivery, they bring a hardware IP position that few SMEs of their size can offer.

Highlights from their portfolio

• SAFE-Infusion
  The largest project by budget (€1.09M EC funding) and the most complete articulation of the company's technology vision — combining air removal, break-away connectors, hazardous drug containment, and remote flow monitoring in a single Innovation Action programme.
• Gasgon
  Coordinator role in an SME-1 feasibility grant that established the core air-bubble-removal concept and directly seeded the larger SAFE-Infusion partnership — a textbook use of the SME Instrument phase 1 as a proof-of-concept launchpad.